A new type of orally active insulin-mimetic vanadyl-porphyrin complex: Meso-tetrakis({4-sulfonatophenyl}porphyrinato)oxovanadium(IV)

Chemistry Letters

Volumn 34, Issue 10, 2005, Pages 1350-1351

  Tapan, Kumar Saha ^a   Adachi, Yusuke ^a   Yoshikawa, Yutaka ^a   Yasui, Hiroyuki ^a   Sakurai, Hiromu ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 29344459634     PISSN: 03667022     EISSN: None     Source Type: Journal    
DOI: 10.1246/cl.2005.1350     Document Type: Article

References (18)

1. S. Wild, G. Roglic, R. Sicree, A. Green, and H. King, "Global Burden of Disease," WHO, Geneva (2003).
2. H. Sakurai, K. Tsuchiya, M. Nukatsuka, J. Kawada, S. Ishikawa, H. Yoshida, and M. Komatsu, J. Clin. Biochem. Nutr., 8, 193 (1990).
3. H. Sakurai, H. Yasui, and Y. Adachi, Expert Opin. Invest. Drugs, 12, 1189 (2003).
4. H. Sakurai, Y. Kojima, Y. Yoshikawa, K. Kawabe, and H. Yasui, Coord. Chem. Rev., 226, 187 (2002).
5. H. Sakurai, Chem. Rec., 2, 237 (2002).
6. K. H. Thompson, J. H. McNeill, and C. Orvig, Chem. Rev., 99, 2561 (1999).
7. L. C. Woo, V. G. Yuen, K. H. Thompson, J. H. McNeill, and C. Orvig, J. Inorg. Biochem., 76, 251 (1999).
8. H. Sakurai, T. Inohara, Y. Adachi, K. Kawabe, H. Yasui, and J. Takada, Bioorg. Med. Chem. Lett., 14, 1093 (2004).
9. A. D. Adler, F. R. Longo, F. Kampas, and J. Kim, J. Inorg. Nucl. Chem., 32, 2443 (1970).
10. -1.
11. D. Matulis and R. Lorrian, Biophys. J., 74, 422 (1998).
12. K. M. Kadish, G. B. Maiya, C. Araullo, and R. Guilard, Inorg. Chem., 28, 2725 (1989).
13. M. Nakai, H. Watanabe, C. Fujiwara, H. Kakegawa, T. Satoh, J. Takada, R. Matsushita, and H. Sakurai, Biol. Pharm. Bull., 18, 719 (1995).
14. Y. Adachi and H. Sakurai, Chem. Pharm. Bull., 52, 428 (2004).
15. K. Takechi, H. Tamura, K. Yamaoka, and H. Sakurai, Free Radical Res., 26, 483 (1997).
16. H. Yasui, A. Tamura, T. Takino, and H. Sakurai, J. Inorg. Biochem., 91, 327 (2002).
17. 1/2 = 5.4 ± 0.6 (min). All parameters of VOTPPS were significantly different from those of VOTMPyP at the 1% level of ANOVA (Analysis of variance; using SPSS 12.0, SPSS Inc.).
18. K. Yamaoka, Y. Tanigawa, and T. Nakagawa, J. Pharmacobio-Dyn., 4, 879 (1981).